MetaVia Inc., a clinical-stage biotechnology company, released its financial results for the first quarter ended March 31, 2025. The company reported a net loss of $3.7 million, compared to a net loss of $6.7 million for the same period in 2024. This translates to $0.36 per basic and diluted share, based on 10,264,202 weighted average shares outstanding, in contrast to $1.32 per share based on 5,089,408 weighted average shares outstanding in the previous year. Total operating expenses decreased significantly to $3.9 million from $6.9 million in the first quarter of 2024. This reduction was primarily due to a drop in research and development (R&D) expenses, which fell to $2.3 million from $4.9 million. General and administrative expenses also decreased to approximately $1.6 million from $2.0 million. MetaVia announced positive top-line results from its Phase 1 MAD trial for DA-1726 in obesity, showing promising weight loss, glucose control, and tolerability. The company plans additional cohorts to determine the maximum tolerated dose. Additionally, MetaVia successfully completed a private placement, generating $10 million in gross proceeds. With $11.2 million in cash at the end of the first quarter, and the additional funds from the private placement, the company expects to be funded into 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.